Epstein Andrew E, Baessler Christina A, Curtis Anne B, Estes N A Mark, Gersh Bernard J, Grubb Blair, Mitchell L Brent
University of Alabama at Birmingham, USA.
Circulation. 2007 Mar 6;115(9):1170-6. doi: 10.1161/CIRCULATIONAHA.106.180203. Epub 2007 Feb 7.
In 1996, the American Heart Association developed a scientific statement entitled "Personal and Public Safety Issues Related to Arrhythmias That May Affect Consciousness: Implications for Regulation and Physician Recommendations." Since then, multiple trials have established the role of implantable cardioverter-defibrillators (ICDs) for the primary prevention of sudden cardiac death in patients at risk for life-threatening ventricular arrhythmias.
The issue of driving for patients with ICDs implanted for primary prevention was briefly discussed in the original statement, with the recommendation that such patients not be restricted from driving beyond the initial phase of healing. This scientific statement has been developed to extend the original 1996 recommendations and to provide specific recommendations on driving for individuals with ICDs implanted for primary prevention.
(1) Patients receiving ICDs for primary prevention should be restricted from driving a private automobile for at least 1 week to allow for recovery from implantation of the defibrillator. Thereafter, these driving privileges should not be restricted in the absence of symptoms potentially related to an arrhythmia. (2) Patients who have received an ICD for primary prevention who subsequently receive an appropriate therapy for ventricular tachycardia or ventricular fibrillation, especially with symptoms of cerebral hypoperfusion, should then be considered to be subject to the driving guidelines previously published for patients who received an ICD for secondary prevention. (3) Patients with ICDs for primary prevention must be instructed that impairment of consciousness is a possible future event. (4) These recommendations do not apply to the licensing of commercial drivers.
1996年,美国心脏协会发表了一份科学声明,题为“与可能影响意识的心律失常相关的个人和公共安全问题:对监管和医生建议的影响”。自那时以来,多项试验确立了植入式心脏复律除颤器(ICD)在对有危及生命的室性心律失常风险的患者进行心脏性猝死一级预防中的作用。
最初的声明中简要讨论了植入ICD进行一级预防的患者的驾驶问题,建议此类患者在愈合的初始阶段之后不应被限制驾驶。本科学声明旨在扩展1996年的原始建议,并为植入ICD进行一级预防的个人提供关于驾驶的具体建议。
(1)接受ICD进行一级预防的患者应被限制驾驶私家车至少1周,以便从除颤器植入中恢复。此后,在没有可能与心律失常相关的症状的情况下,这些驾驶特权不应受到限制。(2)接受ICD进行一级预防,随后接受了针对室性心动过速或心室颤动的适当治疗,尤其是伴有脑灌注不足症状的患者,应被视为受先前为接受ICD进行二级预防的患者发布的驾驶指南的约束。(3)植入ICD进行一级预防的患者必须被告知意识障碍是未来可能发生的事件。(4)这些建议不适用于商业驾驶员的执照发放。